Novartis (NVS) –
-
Novartis (NVS) Announces FDA Approval of Lutathera
-
Novartis (NVS) PT Raised to $108 at CFRA
-
Form 6-K NOVARTIS AG For: Mar 31
-
Novartis (NVS) Tops Q1 EPS by 13c, raises guidance
-
Novartis (NVS) option IV steady into quarter results
-
Novartis (NVS) May 95 straddle into quarter results
-
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
-
New Novartis (NVS) Fabhalta data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgAN
-
EU Regulator Finds No Suicide Risks Linked to Novo's Wegovy - Bloomberg
-
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Trea
-
Novartis to cut 680 jobs in product development
-
Novartis (NVS) shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Adaptimmune Therapeutics (ADAP) Appoints Cintia Piccina as Chief Commercial Officer
-
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
-
New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies
-
BMO Capital Starts Novartis (NVS) at Market Perform, 'Upside Modest for Us'
-
Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis
-
Deutsche Bank Reiterates Buy Rating on Novartis (NOVN:SW) (NVS)
-
FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies
-
Novartis (NVS) PT Lowered to $109 at Morgan Stanley
-
Form S-8 POS NOVARTIS AG
-
Erasca (ERAS) Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
-
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
-
Berenberg Reiterates Hold Rating on Novartis (NOVN:SW) (NVS)
-
The European version of Magnificent 7 is trading at a 30% discount - Goldman
-
Novartis (NVS) to buy German cancer treatment developer MorphoSys for $2.9B
-
MorphoSys AG (MOR) to be Acquired by Novartis for EUR 2.7B Equity Value
-
After-hours movers: Palantir, NXP Semiconductors and more
-
Novartis (NVS) to acquire MorphoSys (MOR) for EUR 68 per share, EUR 2.7bn in cash
-
Midday movers: Estee Lauder, Eli Lilly and more
-
Exclusive-Novartis in the lead to acquire cancer drug developer MorphoSys-sources
-
MorphoSys shares soar on report Novartis is in advanced talks to acquire the company
-
Novartis (NVS) in Advanced Talks to Acquire Morphosys (MOR), Prevails over Incyte (INCY) - Reuters
-
Form SC 13G/A NOVARTIS AG Filed by: BlackRock Inc.
-
Form 6-K NOVARTIS AG For: Dec 31
-
Form 6-K NOVARTIS AG For: Dec 31
-
Form IRANNOTICE NOVARTIS AG
-
Form 20-F NOVARTIS AG For: Dec 31
-
Novartis (NVS) slides as Q4 EPS, revenue miss estimates
-
Novartis (NVS) Misses Q4 EPS by 12c
-
Deutsche Bank Reiterates Buy Rating on Novartis (NOVN:SW) (NVS)
-
UBS Reiterates Buy Rating on Novartis (NOVN:SW) (NVS)
-
Novartis (NVS) option IV flat
-
Novartis (NVS) February 110 straddle priced into quarter results
-
Novartis (NVS) February 110 straddle into quarter results
-
Morgan Stanley Starts Novartis (NVS) at Equalweight
-
Novartis (NOVN:SW) (NVS) PT Raised to CHF105 at Jefferies
-
UBS Assumes Novartis (NOVN:SW) (NVS) at Buy
-
Novartis (NOVN:SW) (NVS) PT Raised to CHF97 at Morgan Stanley
-
After-hours movers: AT&T, Tesla, DocuSign and more
Back to NVS Stock Lookup
